Sort
30,917 grants matching “tumor microenvironment”
[PQC-3] A Metabolic Pathway Activation Marker for Prostate Cancer Prognosis
$700,207David J Beebe · University Of Wisconsin-Madison · R01 · FY2017 · CA
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
$700,147Diane M Simeone · New York University School Of Medicine · R01 · FY2020 · CA
Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia
$700,050Jiyang Yu · St. Jude Children'S Research Hospital · U01 · FY2022 · CA
Physical Models for Cancer Progression
$700,000Devarajan Thirumalai · University Of Texas At Austin · · FY2017 · MPS
Cancer Sampling Index (CaSIX) Project
$700,000David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2013 · CA
A robust platform for multiplexed, subcellular proteomic imaging in human tissue
$700,000Robert Michael Angelo · Stanford University · UH3 · FY2020 · CA
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer
$699,970Gordon B. Mills · Oregon Health & Science University · U01 · FY2019 · CA
Enhancing Dendritic Cell Migration to Draining Sentinel Nodes to Improve Immunotherapy Response in HPV negative HNSCC
$699,929Joseph A Califano · University Of California, San Diego · R01 · FY2025 · CA
Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironment
$699,616Fei Chen · Broad Institute, Inc. · R01 · FY2025 · CA
Personalized vaccine for patients with AML
$699,542David E Avigan · Beth Israel Deaconess Medical Center · R01 · FY2019 · CA
Understanding IDH mutant gliomas
$699,386Jing Wu · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Body composition and breast cancer survival: immune and metabolic biomarkers in breast tumors
$699,075Elizabeth Marjorie Cespedes Feliciano · Kaiser Foundation Research Institute · R01 · FY2020 · CA
Role of FGFR1 signaling in distinct cell lineages in prostate cancer progresssion
$698,955Michael M. Ittmann · Baylor College Of Medicine · U01 · FY2011 · CA
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
$698,751Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2023 · CA
Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer
$698,653Ulrike Peters · Fred Hutchinson Cancer Center · R01 · FY2024 · CA
Investigating Macrophage Molecular and Functional Diversity in Tumor Immunity
$698,575Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Vascularized Islet transplantation NICHE with local immunosuppression for the treatment of type 1 diabetes
$698,529Alessandro Grattoni · Methodist Hospital Research Institute · R01 · FY2023 · DK
Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients with Inoperable Malignant Central Airway Obstruction
$698,487Gal Shafirstein · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center
$698,459William C Hahn · Dana-Farber Cancer Inst · U01 · FY2016 · CA
USE OF ANTI-CAIX/CD70 BISPECIFIC CAR T-CELL FACTORIES TO CHANGE THE TUMOR MICROENVIRONMENT, MITIGATE ON-TARGET OFF-TUMOR TOXICITIES, AND ACHIEVE RCC
$698,272Dana-Farber Cancer Institute, Inc. · · FY2018 · Department of the Army
Defining the role of seed and soil in peritoneal metastasis evolution
$698,050Kamila Naxerova · Harvard Medical School · R01 · FY2024 · CA
Onco-immunologic factors contributing to OPSCC among people living with HIV
$697,916Anju Bansal · University Of Alabama At Birmingham · R01 · FY2025 · DE
Microenvironmental regulation of glioblastoma radiosensitivity
$697,852Philip Tofilon · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Smart and self-reporting clinical nano carriers for drug delivery
$697,845Jan Grimm · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA
Exploiting markers of genomic instability in high-risk pre-invasive ovarian cancer
$697,821Sohrab P Shah · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA